Home > Healthcare > Pharmaceuticals > Vaccines > Live Attenuated Vaccines Market

Live Attenuated Vaccines Market – By Vaccine Type (Bacterial, Viral), Development (Tissue Culture, Embryonated Eggs, Live Animals), Age Group, Mode of Administration, Indication (Tuberculosis, Measles, Rotavirus), End-use – Global Forecast (2024 ­ 2032)

  • Report ID: GMI8782
  • Published Date: Apr 2024
  • Report Format: PDF

Live Attenuated Vaccines Market Size

Live Attenuated Vaccines Market size was valued at USD 14.5 billion in 2023 and is expected to reach USD 35.6 billion by 2032 growing at a CAGR of 10.4% over the analysis period, due to the increasing incidences of viral and bacterial infections worldwide along with growing emphasis on vaccination as a preventive measure.
 

Live Attenuated Vaccines Market

According to the World Health Organization (WHO), the estimated number of people who fell ill with tuberculosis worldwide in 2022 increased to 10.6 million, up from 10.3 million in 2021 and 10.0 million in 2020. The rise in tuberculosis cases highlighted the ongoing challenges in combating this infectious disease and emphasized the need for intensified efforts in prevention, diagnosis, and treatment to address this concerning global health issue. This demand surge, coupled with advancements in vaccine development and distribution infrastructure, has further accelerated market growth.
 

Live attenuated vaccines are a type of vaccine composed of weakened forms of pathogens, typically viruses or bacteria, which are capable of replicating within the body but are attenuated or weakened to a degree that they cause minimal or no disease symptoms. These vaccines stimulate a robust immune response by mimicking natural infections, leading to the production of memory cells that provide long-lasting immunity against the targeted pathogen.
 

Live Attenuated Vaccines Market Trends

  • Governments, healthcare organizations, and individuals are increasingly recognizing the importance of vaccination including influenza vaccines in preventing infectious diseases and promoting public health. For instance, in February 2020, governments led the initiatives, with funding from Gavi, and support from partners like the Vaccine Alliance and the Measles & Rubella Initiative (M&RI), which comprises organizations such as WHO and UNICEF.
     
  • These efforts aimed to focus on children under five years old particularly susceptible to measles and disease. The campaign aimed to immunize approximately 45 million children across seven developing nations in the six months. Thus, by implementing these comprehensive vaccination campaigns, the market is expected to show significant opportunities.
     

Live Attenuated Vaccines Market Analysis

Live Attenuated Vaccines Market, By Vaccine Type, 2021 – 2032 (USD Billion)

Based on the vaccine type, the market is classified into bacterial vaccine and viral vaccine. The viral vaccines segment has asserted its dominance in the global market by securing a significant share and experiencing growth of 10.3% between 2024 - 2032.
 

  • This dominance stems from the higher prevalence of viral diseases globally and the efficacy of live attenuated virus vaccines in inducing robust and long-lasting immune responses.
     
  • Vaccines for diseases such as measles, mumps, rubella, varicella, polio, rotavirus, and yellow fever are among the most widely administered live attenuated virus vaccines. Their widespread use reflects the significant impact of viral diseases on public health and the effectiveness of live attenuated virus vaccines in preventing their transmission and associated morbidity.
     
Live Attenuated Vaccines Market, By Development (2023)

Based on the development, the live attenuated vaccines market is classified into tissue culture, embryonated eggs, and live animals. The tissue culture segment held the largest market share of 42.6% in 2023.
 

  • Tissue culture dominance was attributed to its advantages such as scalability, reduced risk of contamination, and improved consistency in vaccine production. The methods involve growing viruses in cell cultures, ensuring controlled conditions and higher yields.
     
  • This approach addresses concerns as compared to safety and ethical considerations associated with embryonated eggs and live animals. As a result, pharmaceutical companies increasingly favor tissue culture methods, thereby driving its dominance in the market.
     

Based on the mode of administration, the live attenuated vaccines market is classified into oral, injectable, and intranasal. The injectable segment held the largest market share in 2023 and is expected to reach USD 20 billion by 2032.
 

  • Injectable vaccines offer advantages in terms of ease of administration, precise dosage control, and broader applicability across age groups. They are particularly favored for mass vaccination campaigns and routine immunization programs, ensuring efficient delivery of live attenuated vaccines to the population.
     

Based on the age group, the live attenuated vaccines market is classified into pediatrics and adults. The pediatrics segment held the largest market share projecting its dominance throughout the forecast period.
 

  • Pediatrics are highly susceptible to infectious diseases and are often prioritized for vaccination to prevent severe infections, complications, and transmission within communities. For instance, according to the National Institutes of Health (NIH), in the U.S., nearly all children contract respiratory syncytial virus (RSV) by age five, with approximately 58,000 requiring hospitalizations annually.
     
  • This urgency has prompted the development of an effective vaccine for RSV. Therefore, public health initiatives and school vaccination requirements ensure high vaccination coverage among children, thereby shaping market dynamics and vaccination strategies worldwide.
     

Based on the indication, the live attenuated vaccines market is classified into tuberculosis, measles, rotavirus, yellow fever, oral polio, influenza, and other indications. The measles segment is poised to dominate the global market, with an anticipated growth of 10.4% during the analysis period.
 

  • Increasing emphasis on measles vaccination programs worldwide, driven by efforts to achieve higher immunization coverage and limit the spread of the disease will spur the market growth. Also, factors such as rising awareness and international partnerships aimed at eliminating measles contribute to the robust growth projections for this segment.
     

Based on the end-use, the live attenuated vaccines market is categorized into hospitals, specialty clinics, and other end-users. The hospitals segment accounted for 49.1% market share in 2023 and is expected to reach USD 17.6 billion by 2032. The hospital segment is further classified into public and private sectors.
 

  • Hospitals are centers for immunization programs, providing vaccines to both inpatients and outpatients. Equipped with the required infrastructure, skilled healthcare staff, and proper storage facilities, hospitals ensure safe vaccine administration.
     
  • Additionally, public hospitals often play a pivotal role in vaccine distribution, especially in regions with government-funded healthcare systems or extensive vaccination programs. They receive vaccines through national immunization programs or governmental initiatives, ensuring widespread availability to the population.
     
North America Live Attenuated Vaccines Market, 2021 – 2032 (USD Billion)

North America region is projected to maintain its lead in the global live attenuated vaccines market, anticipated to reach USD 12 billion by 2032.
 

  • North America region is poised to maintain a significant dominance with advanced research facilities, and presence of key players. Also, high vaccination coverage rates and government initiatives to promote immunization contribute to market dominance.
     
  • Furthermore, strategic collaborations between pharmaceutical companies and research institutes, coupled with strong investment in R&D, propel innovation in live attenuated vaccines.
     

Live Attenuated Vaccines Market Share

In the live attenuated vaccines industry, numerous key players are engaged in competition to secure market share. They drive innovation through significant R&D investments, striving to introduce novel vaccine formulations and expand their product portfolios. Moreover, supported by robust distribution networks, strategic partnerships, and regulatory approvals, these companies maintain a strong competitive position worldwide, facilitating sustained growth and market leadership.
 

Live Attenuated Vaccines Market Companies

Prominent players operating in the live attenuated vaccines market are as mentioned below:

  • Abbott
  • Bharat Biotech International Limited
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline, plc.
  • Haffkine Biopharmaceutical Corporation Limited
  • HBI
  • Merck & Co.
  • Novartis Pharmaceuticals Corporation
  • Sanofi
  • Serum Institute of India Ltd.
  • Valneva SE
  • Zydus Group
     

Live Attenuated Vaccines Industry News:

  • In November 2023, Valneva SE obtained U.S. FDA approval for its IXCHIQ, a single-dose live-attenuated vaccine, for preventing disease caused by the chikungunya virus in adults aged 18 and above at higher risk. This launch pioneered a new treatment line for chikungunya, introducing innovative solutions in the vaccine industry.
     
  • In May 2023, Biofabri, a Zendal subsidiary, and IAVI signed an agreement for the comprehensive development of the tuberculosis vaccine candidate MTBVAC. IAVI supported the development, global regulatory strategy, and resource mobilization for the program during the agreement. The partnership is expected to enhance tuberculosis vaccine accessibility worldwide.
     

The live attenuated vaccines market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report


Market, By Vaccine Type

  • Bacterial vaccine
  • Viral vaccine

Market, By Development

  • Tissue culture
  • Embryonated eggs
  • Live animals

Market, By Mode of Administration

  • Oral
  • Injectable
  • Intranasal

Market, By Age Group

  • Pediatric
  • Adult

Market, By Indication

  • Tuberculosis
  • Measles
  • Rotavirus
  • Yellow fever
  • Oral polio
  • Influenza
  • Other indications

Market, By End-use

  • Hospitals
    • Public
    • Private
  • Specialty clinics
  • Other end-users

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • Rest of Middle East and Africa

 

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global live attenuated vaccines market crossed USD 14.5 billion in 2023 and is expected to reach USD 35.6 billion by 2032, due to the increasing incidences of viral and bacterial infections worldwide.

The viral vaccines type segment held a significant share in 2023 and is set to grow at 10.3% CAGR between 2024 – 2032, driven by a higher prevalence of viral diseases globally.

North America live attenuated vaccines industry held a decent market share in 2023 and is anticipated to reach USD 12 billion by 2032, owing to the presence of advanced research facilities.

Boehringer Ingelheim International GmbH, GlaxoSmithKline, plc., Haffkine Biopharmaceutical Corporation Limited, HBI, Merck & Co., Sanofi, Serum Institute of India Ltd., Valneva SE, Zydus Group among others

Live Attenuated Vaccines Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 12
  • Tables & Figures: 319
  • Countries covered: 19
  • Pages: 190
 Download PDF